Nuno Farinha
Research Subjects
Nuno Farinha has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Mark Bernstein
2 shared publications- Richard L. Momparler
Département de Pharmacologie-Physiologie, Université de Montréal, Montréal, QC H3C 3J7, Canada
2 shared publications A Bartolo
1 shared publicationAlain Fischer
Hôpital Necker Enfants Malades, 149, rue de Sèvres, 75743 Paris, France
1 shared publicationAlexandra Filopovich
Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio
1 shared publicationAna Catarina Fragoso
Division of Pediatric Surgery, Faculty of Medicine, University of Porto, Hospital S. João, 4200-319 Porto, Portugal
1 shared publication
Latest Publications
- Open Access
- 26 May 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (5) , e0349345
Characteristics and outcome of congenital mesoblastic nephroma: A report of 376 patients registered in the SIOP 93-01, SIOP WT 2001, UK-IMPORT, and AIEOP protocols
Background: Congenital mesoblastic nephroma (CMN) is the most common renal neoplasm diagnosed in the very first months of life. Complete nephrectomy only is the gold standard treatment. Objectives and methods: This retrospective study aimed to explore the characteristics and outcome of CMN patients registered in the SIOP 93–01, SIOP WT 2001, UK-IMPORT, and AIEOP studies (1993–2019). Results: A total of 376 CMN cases were identified, with a median age at diagnosis of 28 days. Stage information was available for 337 patients: 92/337 (27.4%) were diagnosed with stage I, 177/337 (52.6%) with stage II, and 67/337 (20%) with stage III. Among 272 patients with available histological data, 113/272 (41.5%) had classic, 105/272 (38.6%) cellular, and 54/272 (19.9%) mixed subtype. Treatment details were available for 314 patients; 248 (79%) underwent initial surgery, and 66 (21%) received preoperative chemotherapy. Among the latter group, 60% of patients showed a measurable reduction in tumor volume, indicating a favorable response to chemotherapy. The 5-year event-free survival rate was 93.8%, and the overall survival rate was 96.9%. The cumulative 5-year incidence of relapse was 5.3%, with a median time to recurrence of 4 months. Of the 16 relapse cases, 8 were in the cellular subtype, 5 in the mixed subtype, and 3 in the classical subtype. Conclusions: This study confirms that CMN patients have an excellent outcome, with complete surgical resection being curative in the majority of cases. Chemosensitivity is observed in a significant proportion, suggesting that neoadjuvant chemotherapy may be a viable option in selected cases. While age at diagnosis, histological subtype, and survival outcomes are consistent with previous reports, we highlight that recurrences, though infrequent, tend to occur early and are not restricted to the cellular subtype. Further prospective studies and molecular investigations are required to refine clinical management strategies and update treatment recommendations.
- 26 May 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (5) , e0349345
Open AccessCharacteristics and outcome of congenital mesoblastic nephroma: A report of 376 patients registered in the SIOP 93-01, SIOP WT 2001, UK-IMPORT, and AIEOP protocols
Background: Congenital mesoblastic nephroma (CMN) is the most common renal neoplasm diagnosed in the very first months of life. Complete nephrectomy only is the gold standard treatment. Objectives and methods: This retrospective study aimed to explore the characteristics and outcome of CMN patients registered in the SIOP 93–01, SIOP WT 2001, UK-IMPORT, and AIEOP studies (1993–2019). Results: A total of 376 CMN cases were identified, with a median age at diagnosis of 28 days. Stage information was available for 337 patients: 92/337 (27.4%) were diagnosed with stage I, 177/337 (52.6%) with stage II, and 67/337 (20%) with stage III. Among 272 patients with available histological data, 113/272 (41.5%) had classic, 105/272 (38.6%) cellular, and 54/272 (19.9%) mixed subtype. Treatment details were available for 314 patients; 248 (79%) underwent initial surgery, and 66 (21%) received preoperative chemotherapy. Among the latter group, 60% of patients showed a measurable reduction in tumor volume, indicating a favorable response to chemotherapy. The 5-year event-free survival rate was 93.8%, and the overall survival rate was 96.9%. The cumulative 5-year incidence of relapse was 5.3%, with a median time to recurrence of 4 months. Of the 16 relapse cases, 8 were in the cellular subtype, 5 in the mixed subtype, and 3 in the classical subtype. Conclusions: This study confirms that CMN patients have an excellent outcome, with complete surgical resection being curative in the majority of cases. Chemosensitivity is observed in a significant proportion, suggesting that neoadjuvant chemotherapy may be a viable option in selected cases. While age at diagnosis, histological subtype, and survival outcomes are consistent with previous reports, we highlight that recurrences, though infrequent, tend to occur early and are not restricted to the cellular subtype. Further prospective studies and molecular investigations are required to refine clinical management strategies and update treatment recommendations.
- 1 November 2011
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 46 (11) , 2076-2082
Abdominal inflammatory myofibroblastic tumor
- 1 November 2011
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 46 (11) , 2076-2082
Abdominal inflammatory myofibroblastic tumor
- 1 March 2009
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 123 (3) , 836-840
Allogeneic Hematopoietic Stem-Cell Transplantation for Leukocyte Adhesion Deficiency
OBJECTIVES. Leukocyte adhesion deficiency is a rare primary immune disorder caused by defects of the CD18 β-integrin molecule on immune cells. The condition usually presents in early infancy and is characterized by deep tissue infections, leukocytosis with impaired formation of pus, and delayed wound healing. Allogeneic hematopoietic stem-cell transplantation offers the possibility of curative therapy, and with patient numbers at any individual center being limited, we surveyed the transplant experience at 14 centers worldwide. METHODS. The course of 36 children with a confirmed diagnosis of leukocyte adhesion deficiency who underwent hematopoietic stem-cell transplantation between 1993 and 2007 was retrospectively analyzed. Data were collected by the registries of the European Society for Immunodeficiencies/European Group for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research. RESULTS. At a median follow-up of 62 months (extending to 14 years), the overall survival rate was 75%. Myeloablative conditioning regimens were used in 28 patients, and reduced-intensity conditioning in 8 patients, with no deaths in this subgroup. Survival rates after matched family donor and unrelated donor transplants were similar, with 11 of 14 matched family donor and 12 of 14 unrelated donor recipients alive; mortality was greatest after haploidentical transplants, after which 4 of 8 children did not survive. Twenty-seven transplant recipients were alive, with full donor engraftment in 17 cases, mixed multilineage chimerism in 7 patients, and mononuclear cell-restricted chimerism in an additional 3 cases. CONCLUSIONS. Hematopoietic stem-cell transplantation offers long-term benefit in leukocyte adhesion deficiency and should be considered as an early therapeutic option if a suitable HLA-matched stem-cell donation is available. Reduced-intensity conditioning was particularly safe, and mixed-donor chimerism seems sufficient to prevent significant symptoms, although careful long-term monitoring will be required for these patients.
- 1 March 2009
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 123 (3) , 836-840
Allogeneic Hematopoietic Stem-Cell Transplantation for Leukocyte Adhesion Deficiency
OBJECTIVES. Leukocyte adhesion deficiency is a rare primary immune disorder caused by defects of the CD18 β-integrin molecule on immune cells. The condition usually presents in early infancy and is characterized by deep tissue infections, leukocytosis with impaired formation of pus, and delayed wound healing. Allogeneic hematopoietic stem-cell transplantation offers the possibility of curative therapy, and with patient numbers at any individual center being limited, we surveyed the transplant experience at 14 centers worldwide. METHODS. The course of 36 children with a confirmed diagnosis of leukocyte adhesion deficiency who underwent hematopoietic stem-cell transplantation between 1993 and 2007 was retrospectively analyzed. Data were collected by the registries of the European Society for Immunodeficiencies/European Group for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research. RESULTS. At a median follow-up of 62 months (extending to 14 years), the overall survival rate was 75%. Myeloablative conditioning regimens were used in 28 patients, and reduced-intensity conditioning in 8 patients, with no deaths in this subgroup. Survival rates after matched family donor and unrelated donor transplants were similar, with 11 of 14 matched family donor and 12 of 14 unrelated donor recipients alive; mortality was greatest after haploidentical transplants, after which 4 of 8 children did not survive. Twenty-seven transplant recipients were alive, with full donor engraftment in 17 cases, mixed multilineage chimerism in 7 patients, and mononuclear cell-restricted chimerism in an additional 3 cases. CONCLUSIONS. Hematopoietic stem-cell transplantation offers long-term benefit in leukocyte adhesion deficiency and should be considered as an early therapeutic option if a suitable HLA-matched stem-cell donation is available. Reduced-intensity conditioning was particularly safe, and mixed-donor chimerism seems sufficient to prevent significant symptoms, although careful long-term monitoring will be required for these patients.
- 1 May 2006
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 10 (3) , 145-147
Burkitt leukemia with numb chin syndrome and cavernous sinus involvement
- 1 May 2006
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 10 (3) , 145-147
Burkitt leukemia with numb chin syndrome and cavernous sinus involvement
- 16 March 2004
- Vol. 24 (1) , 75-8
Activation of expression of p15, p73 and E-cadherin in leukemic cells by different concentrations of 5-aza-2'-deoxycytidine (Decitabine).
Inactivation of genes that suppress neoplasia by aberrant DNA methylation is a key event that occurs during the development of leukemia. The inhibitor of DNA methylation, 5-aza-2'-deoxycytidine (5AZA), which can re-activate these genes, is under clinical investigation for therapy of leukemia. The objective of this study was to determine the concentrations of 5AZA that will re-activate target silent genes in human leukemic cell lines. RT-PCR was used to evaluate the effect of concentrations of 1 to 100 ng/ml of 5AZA on the re-activation of p15 and p73 in KG1a myeloid leukemic cells and E-cadherin in HL-60 myeloid leukemic cells. The effect of 5AZA on inhibition of growth, DNA synthesis and colony formation in these cell lines was also investigated. The extent of activation of the target genes was dependent on the concentration of 5AZA. For p15, pronounced activation was observed at 10 ng/ml or greater. For p73 and E-cadherin significant activation was observed at 100 ng/ml of 5AZA. Maximal inhibition of growth, DNA synthesis and colony formation occurred at 100 ng/ml. The in vitro antineoplastic and gene re-activation activity of 5AZA is dependent on the concentration of this analog. These data may be helpful in the design of the optimal dose-schedule of 5AZA for the clinical therapy of leukemia.
- 16 March 2004
- Vol. 24 (1) , 75-8
Activation of expression of p15, p73 and E-cadherin in leukemic cells by different concentrations of 5-aza-2'-deoxycytidine (Decitabine).
Inactivation of genes that suppress neoplasia by aberrant DNA methylation is a key event that occurs during the development of leukemia. The inhibitor of DNA methylation, 5-aza-2'-deoxycytidine (5AZA), which can re-activate these genes, is under clinical investigation for therapy of leukemia. The objective of this study was to determine the concentrations of 5AZA that will re-activate target silent genes in human leukemic cell lines. RT-PCR was used to evaluate the effect of concentrations of 1 to 100 ng/ml of 5AZA on the re-activation of p15 and p73 in KG1a myeloid leukemic cells and E-cadherin in HL-60 myeloid leukemic cells. The effect of 5AZA on inhibition of growth, DNA synthesis and colony formation in these cell lines was also investigated. The extent of activation of the target genes was dependent on the concentration of 5AZA. For p15, pronounced activation was observed at 10 ng/ml or greater. For p73 and E-cadherin significant activation was observed at 100 ng/ml of 5AZA. Maximal inhibition of growth, DNA synthesis and colony formation occurred at 100 ng/ml. The in vitro antineoplastic and gene re-activation activity of 5AZA is dependent on the concentration of this analog. These data may be helpful in the design of the optimal dose-schedule of 5AZA for the clinical therapy of leukemia.
- 1 January 2004
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 45 (1) , 147-154
Enhancement of Antineoplastic Action of 5-Aza-2′-deoxycytidine by Phenylbutyrate on L1210 Leukemic Cells
Epigenetic changes, such as aberrant DNA methylation that silences tumor suppressor genes (TSGs), can play an important role in the development of leukemia. The DNA methylation inhibitor, 5-aza-2′-deoxycytidine (5-AZA-CdR), can reactivate these silent TSGs and is an interesting agent to investigate for therapy of leukemia. It has been reported that the effectiveness of 5-AZA-CdR to reactivate TSG can be enhanced by inhibitors of histone deacetylase (HDIs). HDIs can convert a compact chromatin structure to an open configuration that facilitates gene expression. An interesting HDI is phenylbutyrate (PB), which has shown some clinical activity for the therapy of leukemia. In this report we have investigated the antineoplastic activity of 5-AZA-CdR and PB alone and in combination on murine L1210 lymphoid leukemic cells. The in vitro treatment of 5-AZA-CdR and PB in combination produced a greater inhibition of growth, DNA synthesis, and also a greater reduction on colony formation on both L1210 and human HL-60 leukemic cells as compared to either drug alone. The combination also produced a synergistic activation of the TSG, p15CDN2B, in the L1210 cells. In mice with L1210 leukemia the combination showed enhanced antineoplastic activity. We also observed an enhancement of the antineoplastic activity of this combination in mice with L1210 leukemia. These data provide a rationale to investigate 5-AZA-CdR and PB in patients with advanced leukemia.
- 1 January 2004
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 45 (1) , 147-154
Enhancement of Antineoplastic Action of 5-Aza-2′-deoxycytidine by Phenylbutyrate on L1210 Leukemic Cells
Epigenetic changes, such as aberrant DNA methylation that silences tumor suppressor genes (TSGs), can play an important role in the development of leukemia. The DNA methylation inhibitor, 5-aza-2′-deoxycytidine (5-AZA-CdR), can reactivate these silent TSGs and is an interesting agent to investigate for therapy of leukemia. It has been reported that the effectiveness of 5-AZA-CdR to reactivate TSG can be enhanced by inhibitors of histone deacetylase (HDIs). HDIs can convert a compact chromatin structure to an open configuration that facilitates gene expression. An interesting HDI is phenylbutyrate (PB), which has shown some clinical activity for the therapy of leukemia. In this report we have investigated the antineoplastic activity of 5-AZA-CdR and PB alone and in combination on murine L1210 lymphoid leukemic cells. The in vitro treatment of 5-AZA-CdR and PB in combination produced a greater inhibition of growth, DNA synthesis, and also a greater reduction on colony formation on both L1210 and human HL-60 leukemic cells as compared to either drug alone. The combination also produced a synergistic activation of the TSG, p15CDN2B, in the L1210 cells. In mice with L1210 leukemia the combination showed enhanced antineoplastic activity. We also observed an enhancement of the antineoplastic activity of this combination in mice with L1210 leukemia. These data provide a rationale to investigate 5-AZA-CdR and PB in patients with advanced leukemia.
- 1 December 2002
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 30 (12) , 979-981
Unrelated bone marrow transplantation for leukocyte adhesion deficiency
The severe form of leukocyte adhesion deficiency type I (LAD-I) usually leads to death early in life. Allogeneic haematopoietic transplantation is the only cure. Unrelated transplantation has been reported only once. We describe three children with LAD-I transplanted with T cell non-depleted bone marrow from unrelated HLA-matched donors. All patients engrafted, one of them at second transplant. One patient developed grade I and one grade II acute GVHD. Two patients are alive, one of them with a decrease in CD11/CD18 expression. Early referral for HLA-matched unrelated BMT is a reasonable option for patients with LAD-I lacking an HLA-matched related donor.
- 1 December 2002
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 30 (12) , 979-981
Unrelated bone marrow transplantation for leukocyte adhesion deficiency
The severe form of leukocyte adhesion deficiency type I (LAD-I) usually leads to death early in life. Allogeneic haematopoietic transplantation is the only cure. Unrelated transplantation has been reported only once. We describe three children with LAD-I transplanted with T cell non-depleted bone marrow from unrelated HLA-matched donors. All patients engrafted, one of them at second transplant. One patient developed grade I and one grade II acute GVHD. Two patients are alive, one of them with a decrease in CD11/CD18 expression. Early referral for HLA-matched unrelated BMT is a reasonable option for patients with LAD-I lacking an HLA-matched related donor.
- 1 July 2000
- Published by Elsevier in Journal of Infection
- Vol. 41 (1) , 61-68
Tuberculosis of the Central Nervous System in Children: a 20-Year Survey
- 1 July 2000
- Published by Elsevier in Journal of Infection
- Vol. 41 (1) , 61-68
Tuberculosis of the Central Nervous System in Children: a 20-Year Survey
- 19 October 1999
- Published by Wiley in Diagnostic Cytopathology
- Vol. 21 (5) , 362
Renal-Cell Carcinoma: Cytologic Diagnosis in a Child
- 19 October 1999
- Published by Wiley in Diagnostic Cytopathology
- Vol. 21 (5) , 362
Renal-Cell Carcinoma: Cytologic Diagnosis in a Child
- 1 February 1997
- Vol. 10, 157-60
[Acute pericarditis in childhood. The 9-year experience of a tertiary referral center].
Sixteen children, aged 7 months to 12 years, with acute pericarditis, admitted between 1985 and 1993 to a tertiary referral centre were analyzed retrospectively for their presentation, etiology, work-up, management and prognosis. It was found that most of the presenting signs were not specific and were often related to associated diseases such as respiratory tract infections. In 50% of the cases a cause was not found, the others had viral infections (12.5%), tuberculosis (12.5%), Haemophilus influenzae infection (6.25%), Toxocara canis infection (6.25%) and collagen diseases (12.5%). In eight cases non-steroidal anti-inflammatory drugs associated with steroids were given, 7 patients received non-steroidal anti-inflammatory drugs and 1 steroids. The mean follow-up time was 3 years (1 to 5). Six patients had one or more relapses. Five of the 6 patients with relapses were in the group which received steroids. The two patients with tuberculosis underwent pericardiectomy. One child died due to complex heart disease and the remaining 15 were cured. It was concluded that in pericarditis an extensive work-up may not reveal the major etiologies and that long term prognosis is good.
- 1 February 1997
- Vol. 10, 157-60
[Acute pericarditis in childhood. The 9-year experience of a tertiary referral center].
Sixteen children, aged 7 months to 12 years, with acute pericarditis, admitted between 1985 and 1993 to a tertiary referral centre were analyzed retrospectively for their presentation, etiology, work-up, management and prognosis. It was found that most of the presenting signs were not specific and were often related to associated diseases such as respiratory tract infections. In 50% of the cases a cause was not found, the others had viral infections (12.5%), tuberculosis (12.5%), Haemophilus influenzae infection (6.25%), Toxocara canis infection (6.25%) and collagen diseases (12.5%). In eight cases non-steroidal anti-inflammatory drugs associated with steroids were given, 7 patients received non-steroidal anti-inflammatory drugs and 1 steroids. The mean follow-up time was 3 years (1 to 5). Six patients had one or more relapses. Five of the 6 patients with relapses were in the group which received steroids. The two patients with tuberculosis underwent pericardiectomy. One child died due to complex heart disease and the remaining 15 were cured. It was concluded that in pericarditis an extensive work-up may not reveal the major etiologies and that long term prognosis is good.